4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR™), designed to directly compute cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient’s response to therapy.
This unprecedented view into tumor dynamics creates new pathways from clinical use to research and development applications—bringing more effective, personalized therapies to patients. Instead of waiting until after treatment to see whether a regimen worked, QPOR aims to give care teams an early, biologically grounded signal of who is likely to benefit, and who may need a different approach.
4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life.
To help realize that vision at scale, 4D Path has teamed up with AMD and Oracle to make predictive oncology faster, more accessible, and more reliable in clinical trials.
The company’s QPOR™ platform converts standard pathology slides into clear, reproducible biomarkers that predict how a tumor will respond to therapy—without requiring genomic data, extra tissue, or complex GPU-based models.
By running QPOR natively on AMD EPYC™ CPUs through Oracle Cloud Infrastructure, the platform can deliver trial-ready insights at scale, at lower cost, and with the consistency needed across many sites. This approach supports regulatory alignment, simplifies validation, and enables deployment across multiple clinical centers, including community hospitals where most patients actually receive their care.
For trial sponsors and drug developers, this means the ability to identify likely responders and non-responders sooner, design more efficient studies, and bring effective therapies to patients faster.
Already validated in retrospective studies and now in use in prospective trials, QPOR is positioned as a next-generation tool for accelerating drug development, improving patient selection, and enabling more personalized cancer care.
